サマリー

世界の長寿・抗老化療法市場は、2020年には250億8730万ドルとなり、2021年から2030年までのCAGRは6.1%を記録し、2030年には442億3480万ドルに達すると予測されています。
加齢は、時間の経過とともに生理的な完全性と機能が徐々に失われていくことが特徴です。加齢エピジェネティクスとは、DNA配列を変化させることなく、生物の寿命の間に自然に起こる遺伝子発現の変化のことを指します。クロマチンエピジェネティクスにはいくつかの酵素が関与しており、DNAのメチル化やヒストンのメチル化・アセチル化過程に変化をもたらすと言われています。加齢に伴いクロマチンはより活性化され、その結果、DNAメチル化が全体的に減少し、グローバルな遺伝子発現がより緩和されるようである。老化細胞は、白内障、緑内障、神経変性疾患（アルツハイマー病、パーキンソン病）、心血管疾患（CVD、動脈硬化、高血圧）、特発性肺線維症（IPF）、II型糖尿病、肉離れ、骨関節炎、骨粗鬆症、慢性閉塞性肺疾患（COPD）、特定の種類の腫瘍などの多くの老化関連疾患に関係していると言われています。
慢性疾患の有病率の増加、アンチエイジング製品に関する意識の高まり、AI駆動の医療技術の進歩が市場の成長を後押ししています。また、老年人口の増加や、個別化、精密化、予防、参加型の老化治療に対する需要の増加が、市場の成長に向けて寄与しています。しかし、熟練した専門家の不足と組織修復能力の喪失が、市場の成長を妨げる大きな障害となっています。逆に、研究開発におけるセルベースアッセイの需要増は、予測期間中、市場に有利な成長機会を提供すると期待されています。
世界の長寿・抗老化治療市場は、治療法、用途、エンドユーザー、地域に基づいて区分されています。治療法に基づき、老化防止薬物療法、遺伝子療法、免疫療法に分類されます。アプリケーションによって、市場は癌とその他に分類されます。エンドユーザー別では、病院と医療サービス機関に分類されます。地域別では、北米、欧州、アジア太平洋、LAMEAで分析されています。
本レポートで紹介する主要企業は、AgeX Therapeutics Inc.、Bristol-Myers Squibb Company、Calico Life Sciences LLC、CohBar, Inc、Life Biosciences, Inc.、Merck & Co.Inc.、Oisin Biotechnologies、Pfizer, Inc.、T.A. Sciences, Inc.、Unity Biotechnology, Inc.など。
ステークホルダーにとっての主なメリット
本レポートでは、現在の市場動向と2020年から2030年までの将来予測を詳細に定量分析し、有力な市場機会の特定を支援します。
様々な地域の詳細な分析により、現在の動向を詳細に把握し、ステークホルダーが地域別の計画を策定できるようにすることが期待されます。
長寿および抗老化療法市場の成長を促進および抑制する要因の包括的な分析が提供されます。
様々な地域の広範な分析は、企業が戦略的にビジネスの動きを計画することを可能にする洞察を提供します。
主要な市場プレイヤーとその戦略は、市場の競争的展望を理解するために分析されています。
主要市場セグメント
#治療法別
##溶血性薬物療法
##遺伝子治療
##免疫療法
#用途別
##がん
##その他
#エンドユーザー別
##病院
##医療機関
#地域別
##北米
###米国
###カナダ
###メキシコ
##ヨーロッパ
###ドイツ
###フランス
###イギリス
###イタリア
###その他の地域
##アジア太平洋地域
###日本
###中国
###オーストラリア
###インド
###その他のアジア太平洋地域
##ラメア
###ブラジル
###トルコ
###南アフリカ
###LAMEAの残りの地域
主要市場プレイヤー
- エイジックス・セラピューティクス社（AgeX Therapeutics, Inc.
- ブリストル・マイヤーズスクイブ社
- キャリコ・ライフサイエンスLLC
- コバール社
- ライフ・バイオサイエンス社
- メルク・アンド・カンパニーInc.
- オイシン・バイオテクノロジーズ
- ファイザー株式会社
- T.A.サイエンス社
- ユニティ・バイオテクノロジー

ページTOPに戻る

目次

CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET, BY THERAPY
4.1 Overview
4.1.1 Market size and forecast
4.2 Senolytic Drug Therapy
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Gene Therapy
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Immunotherapy
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
CHAPTER 5: LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET, BY APPLICATION
5.1 Overview
5.1.1 Market size and forecast
5.2 Cancer
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Others
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
CHAPTER 6: LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET, BY END USER
6.1 Overview
6.1.1 Market size and forecast
6.2 Hospital
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Medical Service Institution
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
CHAPTER 7: LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 LAMEA
7.2.1 Key trends and opportunities
7.2.2 LAMEA Market size and forecast, by Therapy
7.2.3 LAMEA Market size and forecast, by Application
7.2.4 LAMEA Market size and forecast, by End user
7.2.5 LAMEA Market size and forecast, by country
7.2.5.1 Brazil
7.2.5.1.1 Market size and forecast, by Therapy
7.2.5.1.2 Market size and forecast, by Application
7.2.5.1.3 Market size and forecast, by End user
7.2.5.2 Turkey
7.2.5.2.1 Market size and forecast, by Therapy
7.2.5.2.2 Market size and forecast, by Application
7.2.5.2.3 Market size and forecast, by End user
7.2.5.3 South Africa
7.2.5.3.1 Market size and forecast, by Therapy
7.2.5.3.2 Market size and forecast, by Application
7.2.5.3.3 Market size and forecast, by End user
7.2.5.4 Rest of LAMEA
7.2.5.4.1 Market size and forecast, by Therapy
7.2.5.4.2 Market size and forecast, by Application
7.2.5.4.3 Market size and forecast, by End user
7.3 North America
7.3.1 Key trends and opportunities
7.3.2 North America Market size and forecast, by Therapy
7.3.3 North America Market size and forecast, by Application
7.3.4 North America Market size and forecast, by End user
7.3.5 North America Market size and forecast, by country
7.3.5.1 U.S.
7.3.5.1.1 Market size and forecast, by Therapy
7.3.5.1.2 Market size and forecast, by Application
7.3.5.1.3 Market size and forecast, by End user
7.3.5.2 Canada
7.3.5.2.1 Market size and forecast, by Therapy
7.3.5.2.2 Market size and forecast, by Application
7.3.5.2.3 Market size and forecast, by End user
7.3.5.3 Mexico
7.3.5.3.1 Market size and forecast, by Therapy
7.3.5.3.2 Market size and forecast, by Application
7.3.5.3.3 Market size and forecast, by End user
7.4 Europe
7.4.1 Key trends and opportunities
7.4.2 Europe Market size and forecast, by Therapy
7.4.3 Europe Market size and forecast, by Application
7.4.4 Europe Market size and forecast, by End user
7.4.5 Europe Market size and forecast, by country
7.4.5.1 Germany
7.4.5.1.1 Market size and forecast, by Therapy
7.4.5.1.2 Market size and forecast, by Application
7.4.5.1.3 Market size and forecast, by End user
7.4.5.2 France
7.4.5.2.1 Market size and forecast, by Therapy
7.4.5.2.2 Market size and forecast, by Application
7.4.5.2.3 Market size and forecast, by End user
7.4.5.3 United Kingdom
7.4.5.3.1 Market size and forecast, by Therapy
7.4.5.3.2 Market size and forecast, by Application
7.4.5.3.3 Market size and forecast, by End user
7.4.5.4 Italy
7.4.5.4.1 Market size and forecast, by Therapy
7.4.5.4.2 Market size and forecast, by Application
7.4.5.4.3 Market size and forecast, by End user
7.4.5.5 Rest of Europe
7.4.5.5.1 Market size and forecast, by Therapy
7.4.5.5.2 Market size and forecast, by Application
7.4.5.5.3 Market size and forecast, by End user
7.5 Asia-Pacific
7.5.1 Key trends and opportunities
7.5.2 Asia-Pacific Market size and forecast, by Therapy
7.5.3 Asia-Pacific Market size and forecast, by Application
7.5.4 Asia-Pacific Market size and forecast, by End user
7.5.5 Asia-Pacific Market size and forecast, by country
7.5.5.1 Japan
7.5.5.1.1 Market size and forecast, by Therapy
7.5.5.1.2 Market size and forecast, by Application
7.5.5.1.3 Market size and forecast, by End user
7.5.5.2 China
7.5.5.2.1 Market size and forecast, by Therapy
7.5.5.2.2 Market size and forecast, by Application
7.5.5.2.3 Market size and forecast, by End user
7.5.5.3 Australia
7.5.5.3.1 Market size and forecast, by Therapy
7.5.5.3.2 Market size and forecast, by Application
7.5.5.3.3 Market size and forecast, by End user
7.5.5.4 India
7.5.5.4.1 Market size and forecast, by Therapy
7.5.5.4.2 Market size and forecast, by Application
7.5.5.4.3 Market size and forecast, by End user
7.5.5.5 Rest of Asia-Pacific
7.5.5.5.1 Market size and forecast, by Therapy
7.5.5.5.2 Market size and forecast, by Application
7.5.5.5.3 Market size and forecast, by End user
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 AgeX Therapeutics, Inc.
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Bristol-Myers Squibb Company
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Calico Life Sciences LLC
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 CohBar, Inc.
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Life Biosciences, Inc.
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Merck & Co., Inc.
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Oisin Biotechnologies
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Pfizer Inc.
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 T.A. Sciences, Inc.
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Unity Biotechnology, Inc.
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments


LIST OF TABLES
TABLE 1. GLOBAL LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET, BY THERAPY, 2020-2030,($MILLION)
TABLE 2. LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET REVENUE, FOR SENOLYTIC DRUG THERAPY, BY REGION , 2020-2030,($MILLION)
TABLE 3. LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET SENOLYTIC DRUG THERAPY BY COUNTRY, 2020-2030,($MILLION)
TABLE 4. LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET REVENUE, FOR GENE THERAPY, BY REGION , 2020-2030,($MILLION)
TABLE 5. LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET GENE THERAPY BY COUNTRY, 2020-2030,($MILLION)
TABLE 6. LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET REVENUE, FOR IMMUNOTHERAPY, BY REGION , 2020-2030,($MILLION)
TABLE 7. LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET IMMUNOTHERAPY BY COUNTRY, 2020-2030,($MILLION)
TABLE 8. GLOBAL LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET, BY APPLICATION, 2020-2030,($MILLION)
TABLE 9. LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET REVENUE, FOR CANCER, BY REGION , 2020-2030,($MILLION)
TABLE 10. LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET CANCER BY COUNTRY, 2020-2030,($MILLION)
TABLE 11. LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET REVENUE, FOR OTHERS, BY REGION , 2020-2030,($MILLION)
TABLE 12. LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET OTHERS BY COUNTRY, 2020-2030,($MILLION)
TABLE 13. GLOBAL LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 14. LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET REVENUE, FOR HOSPITAL, BY REGION , 2020-2030,($MILLION)
TABLE 15. LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET HOSPITAL BY COUNTRY, 2020-2030,($MILLION)
TABLE 16. LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET REVENUE, FOR MEDICAL SERVICE INSTITUTION, BY REGION , 2020-2030,($MILLION)
TABLE 17. LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET MEDICAL SERVICE INSTITUTION BY COUNTRY, 2020-2030,($MILLION)
TABLE 18. LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET, BY REGION, 2020-2030,($MILLION)
TABLE 19. LAMEA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET, BY THERAPY, 2020-2030,($MILLION)
TABLE 20. LAMEA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET, BY APPLICATION, 2020-2030,($MILLION)
TABLE 21. LAMEA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 22. LAMEA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 23. BRAZIL LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
TABLE 24. BRAZIL LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 25. BRAZIL LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY END USER 2020-2030,($MILLION)
TABLE 26. TURKEY LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
TABLE 27. TURKEY LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 28. TURKEY LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY END USER 2020-2030,($MILLION)
TABLE 29. SOUTH AFRICA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
TABLE 30. SOUTH AFRICA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 31. SOUTH AFRICA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY END USER 2020-2030,($MILLION)
TABLE 32. REST OF LAMEA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
TABLE 33. REST OF LAMEA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 34. REST OF LAMEA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY END USER 2020-2030,($MILLION)
TABLE 35. NORTH AMERICA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET, BY THERAPY, 2020-2030,($MILLION)
TABLE 36. NORTH AMERICA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET, BY APPLICATION, 2020-2030,($MILLION)
TABLE 37. NORTH AMERICA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 38. NORTH AMERICA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 39. U.S. LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
TABLE 40. U.S. LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 41. U.S. LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY END USER 2020-2030,($MILLION)
TABLE 42. CANADA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
TABLE 43. CANADA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 44. CANADA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY END USER 2020-2030,($MILLION)
TABLE 45. MEXICO LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
TABLE 46. MEXICO LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 47. MEXICO LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY END USER 2020-2030,($MILLION)
TABLE 48. EUROPE LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET, BY THERAPY, 2020-2030,($MILLION)
TABLE 49. EUROPE LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET, BY APPLICATION, 2020-2030,($MILLION)
TABLE 50. EUROPE LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 51. EUROPE LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 52. GERMANY LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
TABLE 53. GERMANY LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 54. GERMANY LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY END USER 2020-2030,($MILLION)
TABLE 55. FRANCE LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
TABLE 56. FRANCE LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 57. FRANCE LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY END USER 2020-2030,($MILLION)
TABLE 58. UNITED KINGDOM LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
TABLE 59. UNITED KINGDOM LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 60. UNITED KINGDOM LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY END USER 2020-2030,($MILLION)
TABLE 61. ITALY LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
TABLE 62. ITALY LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 63. ITALY LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY END USER 2020-2030,($MILLION)
TABLE 64. REST OF EUROPE LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
TABLE 65. REST OF EUROPE LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 66. REST OF EUROPE LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY END USER 2020-2030,($MILLION)
TABLE 67. ASIA-PACIFIC LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET, BY THERAPY, 2020-2030,($MILLION)
TABLE 68. ASIA-PACIFIC LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET, BY APPLICATION, 2020-2030,($MILLION)
TABLE 69. ASIA-PACIFIC LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 70. ASIA-PACIFIC LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 71. JAPAN LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
TABLE 72. JAPAN LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 73. JAPAN LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY END USER 2020-2030,($MILLION)
TABLE 74. CHINA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
TABLE 75. CHINA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 76. CHINA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY END USER 2020-2030,($MILLION)
TABLE 77. AUSTRALIA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
TABLE 78. AUSTRALIA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 79. AUSTRALIA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY END USER 2020-2030,($MILLION)
TABLE 80. INDIA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
TABLE 81. INDIA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 82. INDIA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY END USER 2020-2030,($MILLION)
TABLE 83. REST OF ASIA-PACIFIC LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
TABLE 84. REST OF ASIA-PACIFIC LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 85. REST OF ASIA-PACIFIC LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY END USER 2020-2030,($MILLION)
TABLE 86.AGEX THERAPEUTICS, INC.: COMPANY SNAPSHOT
TABLE 87.AGEX THERAPEUTICS, INC.: OPERATING SEGMENTS
TABLE 88.AGEX THERAPEUTICS, INC.: PRODUCT PORTFOLIO
TABLE 89.AGEX THERAPEUTICS, INC.: NET SALES,
TABLE 90.AGEX THERAPEUTICS, INC.: KEY STRATERGIES
TABLE 91.BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
TABLE 92.BRISTOL-MYERS SQUIBB COMPANY: OPERATING SEGMENTS
TABLE 93.BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
TABLE 94.BRISTOL-MYERS SQUIBB COMPANY: NET SALES,
TABLE 95.BRISTOL-MYERS SQUIBB COMPANY: KEY STRATERGIES
TABLE 96.CALICO LIFE SCIENCES LLC: COMPANY SNAPSHOT
TABLE 97.CALICO LIFE SCIENCES LLC: OPERATING SEGMENTS
TABLE 98.CALICO LIFE SCIENCES LLC: PRODUCT PORTFOLIO
TABLE 99.CALICO LIFE SCIENCES LLC: NET SALES,
TABLE 100.CALICO LIFE SCIENCES LLC: KEY STRATERGIES
TABLE 101.COHBAR, INC.: COMPANY SNAPSHOT
TABLE 102.COHBAR, INC.: OPERATING SEGMENTS
TABLE 103.COHBAR, INC.: PRODUCT PORTFOLIO
TABLE 104.COHBAR, INC.: NET SALES,
TABLE 105.COHBAR, INC.: KEY STRATERGIES
TABLE 106.LIFE BIOSCIENCES, INC.: COMPANY SNAPSHOT
TABLE 107.LIFE BIOSCIENCES, INC.: OPERATING SEGMENTS
TABLE 108.LIFE BIOSCIENCES, INC.: PRODUCT PORTFOLIO
TABLE 109.LIFE BIOSCIENCES, INC.: NET SALES,
TABLE 110.LIFE BIOSCIENCES, INC.: KEY STRATERGIES
TABLE 111.MERCK & CO., INC.: COMPANY SNAPSHOT
TABLE 112.MERCK & CO., INC.: OPERATING SEGMENTS
TABLE 113.MERCK & CO., INC.: PRODUCT PORTFOLIO
TABLE 114.MERCK & CO., INC.: NET SALES,
TABLE 115.MERCK & CO., INC.: KEY STRATERGIES
TABLE 116.OISIN BIOTECHNOLOGIES: COMPANY SNAPSHOT
TABLE 117.OISIN BIOTECHNOLOGIES: OPERATING SEGMENTS
TABLE 118.OISIN BIOTECHNOLOGIES: PRODUCT PORTFOLIO
TABLE 119.OISIN BIOTECHNOLOGIES: NET SALES,
TABLE 120.OISIN BIOTECHNOLOGIES: KEY STRATERGIES
TABLE 121.PFIZER INC.: COMPANY SNAPSHOT
TABLE 122.PFIZER INC.: OPERATING SEGMENTS
TABLE 123.PFIZER INC.: PRODUCT PORTFOLIO
TABLE 124.PFIZER INC.: NET SALES,
TABLE 125.PFIZER INC.: KEY STRATERGIES
TABLE 126.T.A. SCIENCES, INC.: COMPANY SNAPSHOT
TABLE 127.T.A. SCIENCES, INC.: OPERATING SEGMENTS
TABLE 128.T.A. SCIENCES, INC.: PRODUCT PORTFOLIO
TABLE 129.T.A. SCIENCES, INC.: NET SALES,
TABLE 130.T.A. SCIENCES, INC.: KEY STRATERGIES
TABLE 131.UNITY BIOTECHNOLOGY, INC.: COMPANY SNAPSHOT
TABLE 132.UNITY BIOTECHNOLOGY, INC.: OPERATING SEGMENTS
TABLE 133.UNITY BIOTECHNOLOGY, INC.: PRODUCT PORTFOLIO
TABLE 134.UNITY BIOTECHNOLOGY, INC.: NET SALES,
TABLE 135.UNITY BIOTECHNOLOGY, INC.: KEY STRATERGIES


LIST OF FIGURES
FIGURE 1.LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET SEGMENTATION
FIGURE 2.LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,2020-2030
FIGURE 3.LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,2020-2030
FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
FIGURE 5.PORTER FIVE-1
FIGURE 6.PORTER FIVE-2
FIGURE 7.PORTER FIVE-3
FIGURE 8.PORTER FIVE-4
FIGURE 9.PORTER FIVE-5
FIGURE 10.TOP PLAYER POSITIONING
FIGURE 11.LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11.LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,BY THERAPY,2020(%)
FIGURE 12.COMPARATIVE SHARE ANALYSIS OF SENOLYTIC DRUG THERAPY LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,2020-2030(%)
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,2020-2030(%)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF IMMUNOTHERAPY LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,2020-2030(%)
FIGURE 15.LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,BY APPLICATION,2020(%)
FIGURE 16.COMPARATIVE SHARE ANALYSIS OF CANCER LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,2020-2030(%)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF OTHERS LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,2020-2030(%)
FIGURE 18.LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,BY END USER,2020(%)
FIGURE 19.COMPARATIVE SHARE ANALYSIS OF HOSPITAL LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,2020-2030(%)
FIGURE 20.COMPARATIVE SHARE ANALYSIS OF MEDICAL SERVICE INSTITUTION LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,2020-2030(%)
FIGURE 21.LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY REGION,2020
FIGURE 22.BRAZIL LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,2020-2030($MILLION)
FIGURE 23.TURKEY LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,2020-2030($MILLION)
FIGURE 24.SOUTH AFRICA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,2020-2030($MILLION)
FIGURE 25.REST OF LAMEA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,2020-2030($MILLION)
FIGURE 26.U.S. LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,2020-2030($MILLION)
FIGURE 27.CANADA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,2020-2030($MILLION)
FIGURE 28.MEXICO LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,2020-2030($MILLION)
FIGURE 29.GERMANY LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,2020-2030($MILLION)
FIGURE 30.FRANCE LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,2020-2030($MILLION)
FIGURE 31.UNITED KINGDOM LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,2020-2030($MILLION)
FIGURE 32.ITALY LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,2020-2030($MILLION)
FIGURE 33.REST OF EUROPE LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,2020-2030($MILLION)
FIGURE 34.JAPAN LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,2020-2030($MILLION)
FIGURE 35.CHINA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,2020-2030($MILLION)
FIGURE 36.AUSTRALIA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,2020-2030($MILLION)
FIGURE 37.INDIA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,2020-2030($MILLION)
FIGURE 38.REST OF ASIA-PACIFIC LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,2020-2030($MILLION)
FIGURE 39. TOP WINNING STRATEGIES, BY YEAR
FIGURE 40. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 41. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 42.PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 43.COMPETITIVE DASHBOARD
FIGURE 44.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 45.AGEX THERAPEUTICS, INC..: NET SALES ,($MILLION)
FIGURE 46.BRISTOL-MYERS SQUIBB COMPANY.: NET SALES ,($MILLION)
FIGURE 47.CALICO LIFE SCIENCES LLC.: NET SALES ,($MILLION)
FIGURE 48.COHBAR, INC..: NET SALES ,($MILLION)
FIGURE 49.LIFE BIOSCIENCES, INC..: NET SALES ,($MILLION)
FIGURE 50.MERCK & CO., INC..: NET SALES ,($MILLION)
FIGURE 51.OISIN BIOTECHNOLOGIES.: NET SALES ,($MILLION)
FIGURE 52.PFIZER INC..: NET SALES ,($MILLION)
FIGURE 53.T.A. SCIENCES, INC..: NET SALES ,($MILLION)
FIGURE 54.UNITY BIOTECHNOLOGY, INC..: NET SALES ,($MILLION)